secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001193125-25-325821
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GSK files NDA resubmission for tebipenem HBr; Spero to receive $25M milestone in Q1 2026
--------------------------------------------------------------------------------

- GSK resubmitted NDA to FDA for oral carbapenem tebipenem HBr for cUTI/pyelonephritis.
- Resubmission triggers $25 million milestone payment to Spero, expected Q1 2026.
- Spero's tebipenem HBr is investigational; approval not guaranteed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/0001193125-25-325821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/d212013d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-325821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer